Kyorin Pharmaceutical Co., Ltd. (協和キリン株式会社, Kyōrin Kirin Kabushiki-gaisha) is a Japanese pharmaceutical company headquartered in Tokyo, Japan. The company was established in 1949 and operates as a subsidiary of Kyorin Holdings, Inc. Kyorin focuses on the development and manufacturing of pharmaceutical products primarily in the fields of nephrology, urology, and immunology, with expanding interests in neurology and neurodegenerative diseases.
| Attribute | Details |
|---|---|
| Headquarters | Tokyo, Japan |
| Founded | 1949 |
| Stock Ticker | TSE: 4569 |
| Revenue | ¥85.6 billion (FY2023) |
| Employees | ~3,500 |
| CEO | Masahiko Taki |
| Website | www.kyorin-pharm.co.jp |
Kyorin Pharmaceutical has evolved through several key phases since its founding:
Founded as Kyorin Seiyaku Co., Ltd., the company initially focused on generic pharmaceutical products. During this period, Kyorin established its manufacturing capabilities and built a domestic distribution network across Japan.
In 1988, Kyorin merged with Kirin Brewery's pharmaceutical division, creating the modern Kyorin Pharmaceutical. This merger provided access to Kirin's research capabilities and financial resources, enabling expansion into innovative drug development.
Kyorin has shifted focus toward specialty pharmaceuticals, particularly in nephrology and immunology. Recent years have seen increased interest in neurology, including Alzheimer's disease and Parkinson's disease research programs.
Kyorin's primary focus has been on kidney disease treatments. The company's flagship product in this area includes drugs for chronic kidney disease (CKD) and dialysis-related complications.
The immunology division develops treatments for autoimmune diseases and inflammatory conditions. This research has potential applications in neuroinflammation, a key component of neurodegenerative diseases.
Kyorin has recently entered the neurodegeneration space through academic partnerships and internal research programs targeting:
Kyorin markets several pharmaceutical products across therapeutic areas:
| Compound | Indication | Development Stage | Target |
|---|---|---|---|
| KRM-100 | Alzheimer's Disease | Preclinical | Amyloid-beta |
| KRM-200 | Parkinson's Disease | Preclinical | Alpha-synuclein |
| KRM-300 | Neuroinflammation | Discovery | TREM2 |
Kyorin collaborates with Japanese universities and research institutions:
Kyorin has established partnerships with international pharmaceutical companies:
Kyorin Pharmaceutical has maintained steady financial performance:
The company has increased R&D spending on neurology programs in recent years, reflecting its strategic interest in neurodegeneration.
Kyorin is committed to healthcare access and research funding:
Kyorin Pharmaceutical is positioning itself for growth in the neurodegenerative disease market through: